NATAP | 1 hour ago
One third of men who have sex with men (MSM) using daily oral PrEP for a year or more would "definitely switch" to a long-acting PrEP shot every 3 months, while another third would "probably switch," according to results of a 90-man survey. Hispanic and nonwhite men were significantly more likely to be among definite switchers.
Medscape (requires free registration) | 2 hours ago
The long-acting injectable cabotegravir (ViiV Healthcare), a novel HIV prevention therapy, can persist in the body for more than a year in some people, surprising new data from the phase 2a ÉCLAIR study show. "It's an important finding because you need to give patients some sense of when that protection ends," said Jeanne Marrazzo, MD, from the University of Alabama at Birmingham.
Tuberculosis and HIV
Treatment Action Group | 6 hours ago
Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to Treatment Action Group’s 2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time to Lose.
- Médecins Sans Frontières (MSF) International | 6 hours ago
Access to the new tuberculosis (TB) drugs remains severely limited worldwide, but MSF hopes its experience can inform and encourage wider use, while needed clinical research continues.
Project Inform | 18 hours ago
The Centers for Disease Control and Prevention (CDC) just published a report on the rates of chlamydia, gonorrhea and syphilis in 2015, finding the highest number of case reports on these infections in 20 years and a steep increase over the last reported period in 2014. Is this a cause for concern? Absolutely. But, as will inevitably be the case, there are going to be questions about whether increasing use of pre-exposure prophylaxis (PrEP) is to blame and the answer is pretty conclusively “no” as far as one can tell from the available data and the CDC as much as says so.
Science Speaks | 25 October 2016
Kenya’s medical circumcision program launched early with ambition, charting circumcisions performed for 1.3 million men by the end of 2015, leaving evaluators asking what is and what will be the impact of this HIV prevention intervention on the epidemic?
GGD Amsterdam | 24 October 2016
Last year the Public Health Service of Amsterdam (GGD) started the Amsterdam PrEP project, a research project focused on the applicability of PrEP for HIV prevention among men who have sex with men (MSM) and transgender individuals. We now have a picture of the first 200 participants and of national developments over the past year. Almost three-quarters of participants preferred daily PrEP to event-based use (before and after sex). PrEP protected almost all participants from HIV. Two participants contracted an HIV infection in the past year.
(To read the press release in English, click the link on the right-hand side of the page).
HIV Scotland | 24 October 2016
Last week, a report recommending PrEP for use in Scotland was endorsed by the Executive Leads Network, who govern Scotland's Sexual Health and Blood Borne Virus Framework. The report was written by the Scottish HIV PrEP Short Life Working Group (SLWG), administered by HIV Scotland and chaired by Dr Rak Nandwani.
New and experimental HIV treatments
Science Daily | 24 October 2016
New research led by the University of Liverpool aims to improve the administration and availability of drug therapies to HIV patients through the use of nanotechnology.
Hepatitis C treatment
Business Insider | 24 October 2016
Georgia, a country nestled against the Black Sea between Turkey and Russia with a population of 3.7 million, has since taken on a public health effort to help reduce its prevalence of hepatitis C (HCV for short) by 90% by 2020.